Cellectis S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CLLS | ALLO | LYEL | HURA | CHRS | IMMP | |
|---|---|---|---|---|---|---|
| Market cap | 117.86M | 411.13M | 378.11M | 109.61M | 131.36M | 21.74M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.9 | -1.9 | -2.4 | -2.8 | -1.3 | -0.9 |
| Price/book | 2.1 | 0.9 | 1.5 | 6.0 | 2.2 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −66.56% | +0.90% | −34.89% | −33.80% | −42.95% | −91.38% |
| Today | +7.34% | +6.25% | +43.27% | +3.93% | +5.54% | −1.50% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CLLS news ›Cellectis' .HEAL-101 Lowers Triglycerides In Preclinical Study; Phase 1 Data Expected In H2'27
Cellectis S.A. (CLLS) on Tuesday reported expanded preclinical data showing its gene-editing candidate, .HEAL-101 reduced triglyceride levels in a mouse model of severe hypertriglyceridemia. Severe hypertriglyceridemia involves very high…
Cellectis Showcases Promising One-Time Gene Editing Approach for Severe Hypertriglyceridemia
Cellectis SA ( (FR:ALCLS) ) has provided an announcement. Cellectis has unveiled expanded preclinical data for .HEAL-101, an in vivo TALE base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of…
Cellectis Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026
Key findings presented at ESGCT These preclinical results support the continued development of .HEAL-101. Cellectis plans to initiate a Phase 1 investigator-initiated trial (IIT) in China with preliminary clinical data expected in the…
Cellectis downgraded to Underweight from Overweight at Barclays
Barclays analyst Lukas Shumway double downgraded Cellectis (CLLS) to Underweight from Overweight with a price target of $1.30, down from $9. Cel... Cellectis downgraded to Underweight from Overweight at Barclays Barclays analyst Lukas…
Cellectis price target lowered to $3 from $4 at Wells Fargo
Wells Fargo analyst Nick Abbott lowered the firm’s price target on Cellectis (CLLS) to $3 from $4 and keeps an Equal Weight rating on the shares... Cellectis price target lowered to $3 from $4 at Wells Fargo Wells Fargo analyst Nick Abbott…
Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Target Price of $5.46 According to Analysts
Posted by Danessa Lincoln on Oct 25th, 2026 Check Out Our Latest Analysis on CLLS Cellectis stock opened at $0.98 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 1.61. The firm has a…
Multiple Myeloma Pipeline 2026: Who Is Leading the Race? Top Companies and Emerging Therapies to Watch by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics
Albany New York October 20 2026 As per DelveInsight s assessment globally Multiple Myeloma pipeline constitutes 75 key companies continuously working towards developing 80 Multiple Myeloma treatment therapies analysis of Clinical Trials…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS). Such investors are... NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims…
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Securities Fraud Investigation Into Cellectis S.A. (CLLS) GlobeNewswire 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R Cruz continues its investigation of Cellectis S.A (âCellectisâ or the âCompanyâ) (NASDAQ: CLLS) on…
Law firm probes Cellectis over stock drop after halting CAR-T therapy development
Pomerantz LLP is investigating Cellectis S.A. for potential securities fraud following the company's announcement to prioritize in vivo gene editing therapies and discontinue CAR-T cell therapies. This decision caused Cellectis's ADR price…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com4
- openpr.com2
- globenewswire.com1
- pluang.com1
- prnewswire.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.